Radar · Life Sciences in Tel Aviv
Best Life Sciences Companies in Tel Aviv, Israel
The 285 best Life Sciences companies in Tel Aviv, Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: MValve Technologies.
By Rohit KhannaTrends & Stories
285companies tracked
$1.6Bdisclosed funding
0unicorns
84have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × TEL AVIV
Our analysis of 50 Life Sciences companies
$2.2b in tracked funding; 75% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2024.
50companies analysed
75%cloud-native stacks
2024funding peak (by rounds)
1unicorns
2014median founding year
185kcombined LinkedIn audience
34%of audience held by top 3
4companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Tel Aviv
| # | Company | Disclosed funding | Last round | Stage | Employees | Founded | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | MValve Technologies Stealth startup focused on Mitral Regurgitation solutions | $215M | 128 mo ago | Acqui-Hired | 13 | 2012 | 29 patents Transcatheter cardiac valve support structures, sealing and delivery systems for heart valve implants | — |
| 2 | Prilenia Developer of therapeutics for the treatment of neurogenerative diseases | $134M | 55 mo ago | Series B | 39 | 2018 | — | — |
| 3 | Scopio Labs Developer of digital imaging platforms for hematology 83AI top 15%Funding top 19%Product top 21%Moat top 28% All 11 signals ▾AItop 15% Fundingtop 19% Producttop 21% Moattop 28% Techtop 29% Patentstop 31% Innovationtop 34% Growthtop 35% Markettop 45% Globalbottom 43% Newsbottom 17% AI: Holds AI/ML patents (G06N-family CPC) Funding: Raised $115M across 7 rounds · 7 rounds over 9 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 83/100 | $115M | 10 mo ago | Series D | 124 | 2014 | 72 patents Automated digital microscopy imaging and slide handling for high‑throughput pathology | 1 launch · 1 award |
| 4 | Orasis Pharmaceuticals Developer of reformulated eye drops for the treatment of Presbyopia 32Funding top 24%Moat top 32%Product top 40%Talent top 41% All 11 signals ▾Fundingtop 24% Moattop 32% Producttop 40% Talenttop 41% Patentstop 47% Globalbottom 45% Techbottom 44% Innovationbottom 40% Growthbottom 40% Marketbottom 34% Newsbottom 21% Funding: Raised $111M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 31 patents rank vs industry peers · Fliar Intelligence Index 32/100 | $111M | 20 mo ago | Series D | 24 | 2015 | 31 patents Formulating and delivering ophthalmic drugs for eye disease treatment. | 1 launch |
| 5 | Intuition Robotics Provider of an AI-based social robot that acts as a companion for the elderly | $83M | 33 mo ago | Series C | 74 | 2015 | 54 patents Adaptive human‑robot interaction: user availability detection, emotional gestures, personalized device behavior | — |
| 6 | BlueWind Medical Developer of neurostimulation device for the treatment of overactive bladder 50Patents top 39%Funding top 40%Innovation top 43%Tech top 46% All 9 signals ▾Patentstop 39% Fundingtop 40% Innovationtop 43% Techtop 46% Moattop 47% Markettop 50% Talentbottom 49% Globalbottom 40% Newsbottom 22% Patents: 73 patents matched (strict assignee match) · 23 filings since 2022 vs 38 in 2017-21 Funding: Raised $64.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $64M | 1 mo ago | Series B | 95 | 2010 | 73 patents Wireless implantable neurostimulation devices and antenna designs for neuromodulation therapy. | 1 launch |
| 7 | Alpha Tau Medical Developer of radiotherapy technique for the treatment of solid cancer tumors 62Patents top 14%Innovation top 24%Funding top 26%Moat top 26% All 10 signals ▾Patentstop 14% Innovationtop 24% Fundingtop 26% Moattop 26% Techtop 43% Growthtop 48% Marketbottom 49% Talentbottom 49% Globalbottom 45% Newsbottom 21% Patents: 332 patents matched (strict assignee match) · 279 filings since 2022 vs 53 in 2017-21 Innovation: 332 patents (top 8% of patent-holders) · 279 filings since 2022 vs 53 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $55M | 13 mo ago | Public | 89 | 2015 | 332 patents Alpha-emitting radiopharmaceuticals and delivery devices for targeted cancer therapy | 1 partnership |
| 8 | NUVO Developer of cloud-based maternal-fetal monitoring sensors | $55M | 59 mo ago | Series B | 72 | 2014 | 137 patents Prenatal bio-potential sensing and fetal/maternal uterine activity monitoring devices | 1 launch |
| 9 | Valtech Portfolio of valve repair and replacement solutions | $48M | 124 mo ago | Acquired | 40 | 2006 | — | — |
| 10 | Radiaction Digital platform revolutionizing radiation protection for interventional medical teams | $46M | 33 mo ago | Series C | 25 | 2014 | 54 patents Provides deployable radiation shielding for medical imaging and therapy equipment. | — |
| 11 | Eloxx Pharmaceuticals Developer of small molecule drugs for genetic diseases caused by nonsense mutations | $38M | 50 mo ago | Acquired | 15 | 2013 | 63 patents Scalable synthesis and therapeutic application of pseudo‑trisaccharide aminoglycoside antibiotics for genetic disorders | — |
| 12 | Azura Ophthalmics Developing therapies for meibomian gland dysfunction | $37M | 67 mo ago | Series C | 11 | 1997 | 206 patents Patents concentrated in health & consumer products | — |
| 13 | Quris Ai AI-based drug candidate predicting tool for healthcare professionals | $37M | 41 mo ago | Seed | 45 | 2020 | — | — |
| 14 | Vensica Medical Developer of drug delivery catheter for bladder conditions 19Patents top 39%Innovation top 41%Funding top 42%Moat top 44% All 7 signals ▾Patentstop 39% Innovationtop 41% Fundingtop 42% Moattop 44% Globalbottom 43% Techbottom 25% Marketbottom 21% Patents: 27 patents matched (strict assignee match) · 16 filings since 2022 vs 10 in 2017-21 Innovation: 27 patents (top 63% of patent-holders) · 16 filings since 2022 vs 10 in 2017-21 rank vs industry peers · Fliar Intelligence Index 19/100 | $32M | 19 mo ago | Series B | 5 | 2014 | 27 patents Ultrasound‑mediated intravesical drug delivery systems for bladder therapeutics | — |
| 15 | Lutris Pharma Provider of anti-cancer therapy 29Patents top 32%Moat top 32%Funding top 33%Talent top 33% All 9 signals ▾Patentstop 32% Moattop 32% Fundingtop 33% Talenttop 33% Innovationtop 38% Globalbottom 40% Techbottom 31% Newsbottom 18% Marketbottom 17% Patents: 75 patents matched (strict assignee match) · 41 filings since 2022 vs 34 in 2017-21 Moat: Editorial + unicorn rating 4/10 · IP moat: 75 patents rank vs industry peers · Fliar Intelligence Index 29/100 | $30M | 16 mo ago | Series B | 4 | 2016 | 75 patents Topical BRAF kinase inhibitors for EGFR‑related skin toxicities and isoquinoline wound‑healing agents | — |
| 16 | Valcare Medical Developer of minimally-invasive technologies for mitral regurgitation treatment and repair | $28M | 93 mo ago | Series B | 30 | 2012 | — | — |
| 17 | MobileODT Provider of AI-based diagnostic tools for the screening of cervical cancer | $26M | 64 mo ago | Acquired | 18 | 2012 | 26 patents Automated cervical cancer imaging and AI-based detection using enhanced optical illumination. | — |
| 18 | BeaconCure Developer of an AI-enabled statistical analysis platform for biometrics teams 16Moat top 41%Funding top 46%Talent bottom 49%Market bottom 43% All 9 signals ▾Moattop 41% Fundingtop 46% Talentbottom 49% Marketbottom 43% Techbottom 38% Patentsbottom 35% Globalbottom 29% Newsbottom 22% Innovationbottom 21% Moat: Editorial + unicorn rating 7/10 · IP moat: 2 patents Funding: Raised $25.9M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 16/100 | $26M | 17 mo ago | Series C | 27 | 2016 | 2 patents Automated validation and verification of tabular summary reports in software systems | 1 launch |
| 19 | HAGAR Developer of a non-invasive glucometer device for diabetes patients | $25M | 34 mo ago | Series C | — | 2017 | — | — |
| 20 | Z Square Developer of a multi-functional endoscope for imaging & treatment | $25M | 51 mo ago | Series B | 25 | 2013 | 23 patents Advanced multicore fiber endoscopic imaging with spatial encoding and decoding systems | — |
| 21 | Endospan Provider of stent graft endovascular solution for aortic aneurysms | $25M | 127 mo ago | Acquired | 40 | 2009 | 227 patents Branched, fatigue-resistant aortic stent‑grafts for complex endovascular vascular repairs | — |
| 22 | Se-cure Pharmaceuticals Botanical drugs primarily for women's health | $23M | 185 mo ago | Series B | 18 | 1997 | 13 patents Electrical conductivity sensors for seed germination monitoring and viability assessment | — |
| 23 | QuantHealth Provider of AI-based clinical trail management tool for researchers 55AI top 30%Funding top 34%Growth top 35%Moat top 39% All 9 signals ▾AItop 30% Fundingtop 34% Growthtop 35% Moattop 39% Techtop 42% Talentbottom 49% Newsbottom 42% Globalbottom 38% Marketbottom 32% AI: Classified as an AI company · Product described with: ai-based Funding: Raised $22.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 55/100 | $22M | 8 mo ago | Series A | 21 | 2020 | — | 1 award |
| 24 | Protai Provider of AI-enabled platform for proteomics based drug discovery and development | $20M | 39 mo ago | Seed | 11 | 2021 | — | 1 award |
| 25 | Mana.bio AI-based drug delivery technology for research and development | $20M | 32 mo ago | Seed | 17 | 2021 | — | 2 partnerships |
| 26 | RetiSpec Non-invasive eye scanner for early detection of Alzheimer’s Disease. 37Innovation top 38%Funding top 38%Product top 46%Tech bottom 43% All 6 signals ▾Innovationtop 38% Fundingtop 38% Producttop 46% Techbottom 43% Globalbottom 38% Marketbottom 34% Innovation: 2 product lines · Deep-tech classification: Tech Hardware Funding: Raised $17.0M across 3 rounds · 3 rounds over 9 yrs (0.3/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $17M | 22 mo ago | Series A | 23 | 2015 | — | 1 partnership |
| 27 | Filterlex Medical Developer of an embolic protection device | $17M | 53 mo ago | Series B | 11 | 2015 | — | — |
| 28 | ChemomAb Disease targeting mAbs for immune-mediated and fibrotic disorders | $15M | 102 mo ago | Public | 37 | 2011 | 36 patents Therapeutic antibodies targeting CCL24/eotaxin‑2 for liver disease treatment | — |
| 29 | Vectorious Medical Tech Implant for left-atrial monitoring | $14M | 74 mo ago | Acquired | 69 | 2011 | — | — |
| 30 | Therapix Biosciences Developing cannabinoid-based therapies for CNS disorders | $13M | 63 mo ago | Acquired | — | 2014 | 36 patents Novel combination therapeutics using cannabinoids/opioids with N‑acylethanolamines and CD3 antibodies | — |
| 31 | MST Image-based laparoscope positioning system | $12M | 131 mo ago | Acquired | 7 | 2005 | — | — |
| 32 | PainReform Specialty pharmaceutical company that develops products for the treatment of pain 32Product top 24%Funding top 34%Growth top 35%Moat top 38% All 11 signals ▾Producttop 24% Fundingtop 34% Growthtop 35% Moattop 38% Newstop 43% Talentbottom 49% Innovationbottom 44% Techbottom 42% Patentsbottom 39% Globalbottom 35% Marketbottom 21% Product: 2 product launch events in 12 mo · 6 distinct product lines Funding: Raised $12.0M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $12M | 11 mo ago | Public | 6 | 2007 | 22 patents Sustained-release depot formulations for local anesthetics and hydrophobic drugs | — |
| 33 | Perflow Medical Medical devices for neurovascular treatments | $12M | 100 mo ago | Series A | 33 | 2010 | 47 patents Endovascular devices for aneurysm occlusion and removal of vascular blockages. | — |
| 34 | Append Medical Developer of a device for the left atrial appendage closure system | $12M | 35 mo ago | Series A | 10 | 2016 | — | — |
| 35 | Neurolief Wearable device for neurological and neuropsychiatric disorders 27Patents top 36%Talent top 38%Innovation top 39%Funding top 46% All 10 signals ▾Patentstop 36% Talenttop 38% Innovationtop 39% Fundingtop 46% Producttop 47% Moattop 47% Globalbottom 35% Marketbottom 28% Techbottom 26% Newsbottom 22% Patents: 55 patents matched (strict assignee match) · 18 filings since 2022 vs 29 in 2017-21 Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 27/100 | $11M | 2 mo ago | Series A | — | 2012 | 55 patents Wearable transdermal neurostimulation headsets integrating biosensing for therapeutic monitoring | 1 job opening |
| 36 | Vascular Graft Solutions External support technology to improve vein graft longevity and improve outcome of Cardiac bypass surgery. | $11M | 137 mo ago | Series B | 24 | 2009 | 53 patents External vascular graft supports and surgical anastomosis devices for coronary bypass procedures | 2 expansions |
| 37 | SMT Research and Development Embolic protection device | $10M | 182 mo ago | Deadpooled | — | 2004 | — | — |
| 38 | Geneyx Provider of a clinical genetics data management platform for hospitals and genetic labs | $10M | 55 mo ago | Seed | 31 | 2018 | — | — |
| 39 | Leaf Developer of automated hydroponic home grow systems with climate and nutrient control | $9M | 85 mo ago | Series A | 9 | 2015 | — | — |
| 40 | Restore Medical Catheter-delivered implant for treatment of congestive heart failure 42Growth top 30%Patents top 38%Funding top 40%News top 40% All 8 signals ▾Growthtop 30% Patentstop 38% Fundingtop 40% Newstop 40% Innovationtop 44% Moattop 47% Globalbottom 35% Marketbottom 29% Growth: Fresh capital in last 24 mo Patents: 30 patents matched (strict assignee match) · 20 filings since 2022 vs 10 in 2017-21 rank vs industry peers · Fliar Intelligence Index 42/100 | $9M | 11 mo ago | Series B | 9 | 2016 | 30 patents Vascular implant devices for lumenal constriction and controlled release in arteries | — |
| 41 | Promise Provider of AI-based platform for personalised treatment plans 62Talent top 28%AI top 45%Global top 45%Funding top 47% All 6 signals ▾Talenttop 28% AItop 45% Globaltop 45% Fundingtop 47% Moattop 48% Marketbottom 49% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated AI: Product described with: ai-based rank vs industry peers · Fliar Intelligence Index 62/100 | $8M | 18 mo ago | Seed | — | 2020 | — | — |
| 42 | Cassidy Bio Developer of an AI-powered platform for therapeutic-grade gene editing design 69Talent top 28%AI top 45%Funding top 47%Global bottom 48% All 4 signals ▾Talenttop 28% AItop 45% Fundingtop 47% Globalbottom 48% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated AI: Product described with: ai-powered rank vs industry peers · Fliar Intelligence Index 69/100 | $8M | 6 mo ago | Seed | — | 2024 | — | — |
| 43 | Nutrino AI-powered personalized nutrition insights for individuals, businesses, and healthcare professionals | $8M | 98 mo ago | Acquired | 2 | 2011 | — | — |
| 44 | Respinova Acoustic waves to reopen small airways | $7M | 39 mo ago | Deadpooled | 5 | 2008 | 40 patents Inhaled drug delivery systems, especially pulsating inhalers for respiratory and cardiopulmonary therapies. | — |
| 45 | CoreBone Developer of a bioactive, coral-based bone graft material | $4M | 56 mo ago | Series A | 5 | 2012 | 5 patents Bioactive coral-derived bone grafts for orthopedic defect repair | — |
| 46 | IdentifAI Provider of a non-invasive prenatal screening test for genetic syndromes | $3M | 18 mo ago | Series A | 12 | 2020 | — | 1 job opening · 1 award |
| 47 | OutSense Diagnostics Provider of AI-powered IoT devices for diagnostics | $3M | 60 mo ago | Series A | 8 | 2016 | 54 patents Non‑invasive toilet‑based microfluidic analysis of urine/fecal biomarkers for health diagnostics | — |
| 48 | PatenSee Developer of a contactless surveillance system for dialysis patients | $2M | 28 mo ago | Seed | 6 | 2019 | 13 patents Intravascular sensors for real-time blood vessel functional monitoring | 1 partnership |
| 49 | InnoCan Pharma Developer of pharmaceutical products for human and animal health, and wellness | $800K | 14 mo ago | Public | 11 | 2017 | 38 patents Topical pharmaceutical formulations for skin, scalp, and vaginal therapeutic applications. | — |
| 50 | Cell Source Cell therapy treatments for transplantation, cancer treatment and reversal of vital organ disease 7Funding top 48%Global bottom 38%Market bottom 20% All 3 signals ▾Fundingtop 48% Globalbottom 38% Marketbottom 20% Funding: Raised $398k across 5 rounds · 5 rounds over 11 yrs (0.5/yr) Global: Serving 2 countries incl. United States, Israel rank vs industry peers · Fliar Intelligence Index 7/100 | $398K | 5 mo ago | Public | 1 | 2011 | — | — |
Top 12 Life Sciences companies in Tel Aviv
#1
Series B · Herzliya, Tel Aviv · founded 2010 · 95 employees$64Mraised▾
Series B · Herzliya, Tel Aviv · founded 2010 · 95 employees
Developer of neurostimulation device for the treatment of overactive bladder. The flagship product of the company is "Renova" a wireless device that delivers targeted electric stimulation to the nerve for the treatment of patients with an Overactive Bladder and associated symptoms of urinary urgency and frequency.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Patents
top 39%Funding
top 40%Innovation
top 43%Tech
top 46%Moat
top 47%Market
top 50%Patents: 73 patents matched (strict assignee match) · 23 filings since 2022 vs 38 in 2017-21 · Latest publication 2026
Funding: Raised $64.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) · Last round Series B (May 2026)
Innovation: 73 patents (top 37% of patent-holders) · 23 filings since 2022 vs 38 in 2017-21 · Deep-tech classification: Tech Hardware
Audience (LinkedIn): 21k LinkedIn followers — 11.5% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- May 2026Series B$47.8M
- May 2026Conventional Debt—
- May 2022Series B$64M
Founders & team
Investors
ConvaTec, Rainbow Medical
#2
Series D · Tel Aviv, Tel Aviv · founded 2014 · 124 employees$115Mraised▾
Series D · Tel Aviv, Tel Aviv · founded 2014 · 124 employees
Developer of digital imaging platforms for hematology. The company uses computational photography to capture high-resolution (100X) full-field images of peripheral blood smears (PBS) and bone marrow aspirates (BMA), allowing labs to analyze entire slides without losing resolution or field of view.
Fliar Intelligence Index™ 83how this company ranks against its industry peers
AI
top 15%Funding
top 19%Product
top 21%Moat
top 28%Tech
top 29%Patents
top 31%AI: Holds AI/ML patents (G06N-family CPC)
Funding: Raised $115M across 7 rounds · 7 rounds over 9 yrs (0.8/yr) · Last round Series D (Jul 2025)
Product: 6 distinct product lines · Company stage: Series D
Audience (LinkedIn): 30k LinkedIn followers — 16.1% of this cohort's audience
Activity (LinkedIn): 1 product launches · 1 awards announced in 12 mo
Funding rounds
- Jul 2025Series D$10M
- Jul 2024Series D$42M
- Sep 2022Conventional Debt$15M
- Feb 2022Series C$50M
Investors
Aurum Ventures, OTV, Kreos Capital, OurCrowd, Ilex Medical, Lrinstitutes
Tech stack
AddtoanyAddtoany Share ButtonsAmazon Web ServicesApple Icloud MailCdnjsCloudflare
#3
Series A · Herzliya, Tel Aviv · founded 2012$11Mraised▾
Series A · Herzliya, Tel Aviv · founded 2012
Neurolief is focussed on developing a wearable platform technology for brain neuromodulation. It is developing a wearable device that enables the safe and effective treatment for neuro disorders such as migraine and depression without interfering with the patient's daily activities. As of September 2016, the device is in clinical development.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Patents
top 36%Talent
top 38%Innovation
top 39%Funding
top 46%Product
top 47%Moat
top 47%Patents: 55 patents matched (strict assignee match) · 18 filings since 2022 vs 29 in 2017-21 · Latest publication 2026
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Innovation: 55 patents (top 28% of patent-holders) · 18 filings since 2022 vs 29 in 2017-21 · Deep-tech classification: Tech Hardware
Audience (LinkedIn): 7k LinkedIn followers — 3.7% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Market Access Professional
Funding rounds
- Mar 2026Series A$6M
- Aug 2025Series A$5M
- 2015Seed—
Founders & team
Investors
Terra Venture Partners, Brainsway, KT Squared, Champel Capital
#4
Series A · Tel Aviv, Tel Aviv · founded 2020 · 21 employees$22Mraised▾
Series A · Tel Aviv, Tel Aviv · founded 2020 · 21 employees
Provider of AI-based clinical trail management tool for researchers. It allow users to evaluate each parameter independently, or discover the optimal protocol that maximizes efficacy and safety.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
AI
top 30%Funding
top 34%Growth
top 35%Moat
top 39%Tech
top 42%Talent
bottom 49%AI: Classified as an AI company · Product described with: ai-based
Funding: Raised $22.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) · Last round Series A (Oct 2025)
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 6k LinkedIn followers — 3.5% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Oct 2025Series A—
- Jan 2024Series A$2M
- Aug 2023Series A$15M
- Oct 2022Seed$2.6M
Founders & team
Investors
Pitango, Nina Capital, Atooro, Boston Millennia Partners, Shoni Health Ventures, Bertelsmann Investments
Tech stack
Amazon Web ServicesApple Icloud MailCookiebotDatocmsGoogle AnalyticsGoogle Workspace
#5
Public · Tel Aviv, Tel Aviv · founded 2015 · 89 employees$55Mraised▾
Public · Tel Aviv, Tel Aviv · founded 2015 · 89 employees
Developer of radiotherapy technique for the treatment of solid cancer tumors. The technology, known as Alpha DaRT treats solid tumors with interstitial radioactive seeds which release short-lived alpha-emitting atoms into the tumor continuously. This treatment does not have any effect on the surrounding healthy tissue.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Patents
top 14%Innovation
top 24%Funding
top 26%Moat
top 26%Tech
top 43%Growth
top 48%Patents: 332 patents matched (strict assignee match) · 279 filings since 2022 vs 53 in 2017-21 · Latest publication 2026
Innovation: 332 patents (top 8% of patent-holders) · 279 filings since 2022 vs 53 in 2017-21
Funding: Raised $55.0M across 3 rounds · 3 rounds over 9 yrs (0.3/yr) · Last round Post IPO (Apr 2025)
Audience (LinkedIn): 9k LinkedIn followers — 4.9% of this cohort's audience · 80 engagements/post (2.1× cohort median)
Activity (LinkedIn): 1 partnerships (incl. Tolmar Medical) announced in 12 mo
Funding rounds
- Apr 2025Post IPO$36.9M
- Jun 2020Series B$26M
- Sep 2018Series B$29M
- Jul 2017Series A—
Founders & team
Investors
Shavit Capital, Medison Ventures, OurCrowd, Medison VP, Medison, Oramed
Tech stack
AzureBootstrapCore-JsFacebook PixelGoogle AnalyticsGoogle Call Conversion Tracking
#6
Seed · Tel Aviv, Tel Aviv · founded 2024$8Mraised▾
Seed · Tel Aviv, Tel Aviv · founded 2024
Developer of an AI-powered platform for therapeutic-grade gene editing design. The platform uses a genomic foundation model to predict efficacy, safety, and repair outcomes. It assists in selecting guides, editors, and contexts for therapeutic gene editing. The platform also validates experimental results to strengthen predictive power.
Fliar Intelligence Index™ 69how this company ranks against its industry peers
Talent
top 28%AI
top 45%Funding
top 47%Global
bottom 48%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
AI: Product described with: ai-powered
Funding: Raised $8.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Nov 2025)
Audience (LinkedIn): 1k LinkedIn followers
Funding rounds
- Nov 2025Seed$8M
Founders & team
Investors
Ahren, Lool Ventures, 10D, AION Labs
#7
Series D · Herzliya, Tel Aviv · founded 2015 · 24 employees$111Mraised▾
Series D · Herzliya, Tel Aviv · founded 2015 · 24 employees
Orasis Pharmaceuticals is developing reformulated eye drops for the treatment of Presbyopia. They are developing CSF-1 eye drops that assist in eliminating the use of eyeglasses. It is used as a topical solution directly to the eye which improves the elasticity of crystalline glasses. The candidate is in phase II clinical trials.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Funding
top 24%Moat
top 32%Product
top 40%Talent
top 41%Patents
top 47%Global
bottom 45%Funding: Raised $111M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) · Last round Venture Debt (Oct 2024)
Moat: Editorial + unicorn rating 7/10 · IP moat: 31 patents · 10 curated direct competitors tracked
Product: 0 product launch events in 12 mo, 1 the year before · 2 distinct product lines · Company stage: Series D
Audience (LinkedIn): 8k LinkedIn followers — 4.3% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Oct 2024Venture Debt$10M
- Oct 2024Series D$68M
- Sep 2020Series C$30M
- Jun 2018Series B$13M
Founders & team
Investors
Bluestem Capital, Visionary Ventures, Sequoia Capital, Maverick Ventures, LifeSci Venture Partners, SBI JI
Tech stack
Apple Icloud MailCdnjsCloudflareCore-JsElementorFlickity
#8
Public · Herzliya, Tel Aviv · founded 2007 · 6 employees$12Mraised▾
Public · Herzliya, Tel Aviv · founded 2007 · 6 employees
Painreform is a specialty pharmaceutical company that develops products for the treatment of pain. It is focused on reformulations of established pain drugs by applying unique technologies to prolong and enhance efficacy, reduce adverse effects and increase patients convenience as well as faster return of motor function. Its lead product PRF-110 provides a prolonged action of the local analgesic agent ropivacaine, a generic local analgesic drug. The company has applied for 2 PCT applications on its platform technology and on its lead product
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Product
top 24%Funding
top 34%Growth
top 35%Moat
top 38%News
top 43%Talent
bottom 49%Product: 2 product launch events in 12 mo · 6 distinct product lines · Company stage: Public
Funding: Raised $12.0M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) · Last round Post IPO (Jul 2025)
Growth: 2 acquisition/expansion moves in 24 mo · Fresh capital in last 24 mo
Funding rounds
- Jul 2025Post IPO$600K
- Mar 2021Post IPO$6M
- Jul 2018Series A$12M
Founders & team
Investors
LayerBio, XT Hi-Tech, XT Group, Medica Venture Partners, Viola Partners
Tech stack
WordpressMysqlPhpNginx
#9
Series B · Tel Aviv, Tel Aviv · founded 2016 · 9 employees$9Mraised▾
Series B · Tel Aviv, Tel Aviv · founded 2016 · 9 employees
Restore Medical is an early stage company focussed on developing a catheter-delivered implant for treatment of congestive heart failure (CHF). It is developing its flagship product called ContraBand which claims to provide improved quality of life for patients with left ventricle heart failure. As of December 2016, the company is operating as a portfolio of Incentive & the hasn't disclosed the device development details.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Growth
top 30%Patents
top 38%Funding
top 40%News
top 40%Innovation
top 44%Moat
top 47%Growth: Fresh capital in last 24 mo
Patents: 30 patents matched (strict assignee match) · 20 filings since 2022 vs 10 in 2017-21 · Latest publication 2026
Funding: Raised $9.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) · Last round Series B (Jul 2025)
Audience (LinkedIn): 3k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public)
Funding rounds
- Jul 2025Series B$23M
- Jun 2022Grant (prize money)$2.6M
Investors
Europa, Pitango, European Innovation Council, Peregrine Ventures, Incentive Incubator
#10
Series B · Tel Aviv, Tel Aviv · founded 2016 · 4 employees$30Mraised▾
Series B · Tel Aviv, Tel Aviv · founded 2016 · 4 employees
Lutris Pharma is developing anticancer therapy based on EGFR (Epidermal Growth Factor Receptor) Inhibitors. It helps in reducing dose-limiting side effects mainly dermal toxicity. It develops its proprietary small molecule B-Raf-based inhibitor LUT014, reducing acneiform lesions. It is in phase 1 clinical trial.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Patents
top 32%Moat
top 32%Funding
top 33%Talent
top 33%Innovation
top 38%Global
bottom 40%Patents: 75 patents matched (strict assignee match) · 41 filings since 2022 vs 34 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 4/10 · IP moat: 75 patents
Funding: Raised $30.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series B (Jan 2025)
Audience (LinkedIn): 1k LinkedIn followers
Funding rounds
- Jan 2025Series B$30M
Founders & team
Investors
Columbus Venture Partners, Pontifax, Peregrine Ventures, aMoon, Arkin
#11
Series C · Tel Aviv, Tel Aviv · founded 2016 · 27 employees$25.9Mraised▾
Series C · Tel Aviv, Tel Aviv · founded 2016 · 27 employees
Developer of an AI-enabled statistical analysis platform for biometrics teams. The platform unifies review roles within a fit-for-purpose environment. It enhances visible collaboration, accountability, and efficiency. The AI algorithms are refined through metadata extraction and expert feedback. The platform delivers validation, data transformation, and metadata reuse. An automated activity log maintains a real-time audit trail.
Fliar Intelligence Index™ 16how this company ranks against its industry peers
Moat
top 41%Funding
top 46%Talent
bottom 49%Market
bottom 43%Tech
bottom 38%Patents
bottom 35%Moat: Editorial + unicorn rating 7/10 · IP moat: 2 patents · 9 curated direct competitors tracked
Funding: Raised $25.9M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series C (Jan 2025)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 4k LinkedIn followers — 2.4% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Jan 2025Series C$15M
- Jun 2023Series B$14M
- Mar 2023Series A$9.9M
- Nov 2021Seed$2M
Founders & team
Investors
NewVale Capital
Tech stack
WordpressMysqlPhpWp RocketContact Form 7Yoast Seo
#12
Series B · Tel Aviv, Tel Aviv · founded 2014 · 5 employees$32.5Mraised▾
Series B · Tel Aviv, Tel Aviv · founded 2014 · 5 employees
Developer of drug delivery catheter for a bladder condition. The VensiCare device, drugs are instilled following the delivery of ultrasound to the bladder.
Fliar Intelligence Index™ 19how this company ranks against its industry peers
Patents
top 39%Innovation
top 41%Funding
top 42%Moat
top 44%Global
bottom 43%Tech
bottom 25%Patents: 27 patents matched (strict assignee match) · 16 filings since 2022 vs 10 in 2017-21 · Latest publication 2026
Innovation: 27 patents (top 63% of patent-holders) · 16 filings since 2022 vs 10 in 2017-21 · Deep-tech classification: Tech Hardware
Funding: Raised $32.5M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) · Last round Series B (Nov 2024)
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Nov 2024Series B$11M
- Nov 2021Series B$19M
- Sep 2017Series A$2M
- Jul 2016Seed$500K
Investors
Cogentix Medical, Merz, Israel Biotech Fund, Agriline Products, The Trendlines Group, Laborie Medical
Tech stack
Apache Http ServerCore-JsElementorGodaddyGodaddy Website BuilderHello Elementor
Funding & investor landscape
$1.6Btotal disclosed funding
80companies funded
189disclosed rounds
2rounds last 90 days
Most active investors
Notable founders
Dan Lemaitre
Chairman & CEO · BlueWind Medical
Shmuel Shany
Co-Founder · Neurolief
Scott Drees
CEO · Neurolief
Orr Inbar
Co-Founder & CEO · QuantHealth
Uzi Sofer
CEO · Alpha Tau Medical
Yaniv Shmueli
Co-Founder & CTO · Cassidy Bio
Ayal Hendel
Co-Founder & CSO · Cassidy Bio
Elad Kedar
CEO · Orasis Pharmaceuticals
Michael Mulholland
Chief Executive Officer · PainReform
Antoni Ribas
Founder & Chairman · Lutris Pharma
Noa Shelach
CEO · Lutris Pharma
Ilan Carmeli
COO & Co-Founder · BeaconCure
Prism market signals · Israel · country-scoped Prism corpus, 1,211,671 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · Israel
How research on Biotechnology is moving in Israel
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 267 Israel-affiliated papers.
top research entities
- Ministry of Agriculture118
- Hebrew University of Jerusalem29
- Agricultural Research Organization25
- Tel Aviv University21
- Ben-Gurion University of the Negev19
leading researchers
Itamar Willner · Dombrovsky, A. · Wei Zhao · Goor Sasson · Roy Novoselsky · Shalev Itzkovitz · Xiaoqing Liu · Hengyou Zhang
▲
Breakthroughs69 · 26%
▲ 0%→25% share
0 median citations80% since 2021mostly empirical
Gene research emerged brand-new with 10 papers, driving Breakthroughs segment from 0% to 25% field-share.
rising sub-themes (early→recent)
- Mitochondrion1→5
Newly emergingGene 0→10 · Transcription factor 0→5 · Mutant 0→5
Landmark The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity · 3,514 cites
◆
Advancements119 · 45%
▲ 0%→48% share
0 median citations90% since 2021mostly empirical
Gene studies surged 1→18 papers as Advancements expanded from 0% to 48%, with Transcriptome and Microbiome newly emerging at 8 each.
rising sub-themes (early→recent)
- Gene1→18
- Plant disease resistance1→7
- Resistance (ecology)2→6
Newly emergingTranscriptome 0→8 · Microbiome 0→8 · Selection (genetic algorithm) 0→7
Landmark Plant Growth-Promoting Rhizobacteria: Context, Mechanisms of Action, and Roadmap to Commercialization of Biostimulants f · 1,849 cites
▼
Concerns43 · 16%
▲ 0%→14% share
0 median citations74% since 2021mostly reviews
Agriculture concerns are intensifying — papers doubled from 3 to 6 as Concerns segment grew from 0% to 14%.
rising sub-themes (early→recent)
- Agriculture3→6
Landmark Genetic Engineering for Modern Agriculture: Challenges and Perspectives · 1,148 cites
RESEARCH HOTSPOTS · Israel
Where biotechnology is researched across Israel
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Jerusalem29 · +0.39
Tel Aviv27 · +0.41
Beer Sheva19 · +0.60
Haifa17 · +0.40
Rehovot16 · +0.53
Common questions
How many Life Sciences companies are there in Tel Aviv, Israel?
Radar tracks 285 indexable Life Sciences companies headquartered in Tel Aviv, Israel that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Tel Aviv, Israel?
The Life Sciences companies in Tel Aviv, Israel on this list have raised a combined $1.6B in disclosed equity funding across 80 funded companies.
Which is the highest-funded Life Sciences company in Tel Aviv, Israel?
MValve Technologies is the highest-funded Life Sciences company in Tel Aviv, Israel, with $215M in disclosed equity funding.
How many Life Sciences companies in Tel Aviv, Israel are funded?
80 of the 285 Life Sciences companies in Tel Aviv, Israel on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Tel Aviv, Israel?
None of the Life Sciences companies in Tel Aviv, Israel on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Tel Aviv, Israel Life Sciences companies?
The most active investors in Tel Aviv, Israel Life Sciences companies on this list include Europa, RAD BioMed, Peregrine Ventures, EIC Fund, Incentive Incubator.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.